	US 12,007,393 B2
	Methods based on the detection of RAD51 foci in tumor cells
Violeta Serra Elizalde, Barcelona (ES); Judith Balmaña Gelpi, Barcelona (ES); Cristina Cruz Zambrano, Barcelona (ES); Alba Llop Guevara, Barcelona (ES); Marta Castroviejo Bermejo, Logroño (ES); Mark J. O'Connor, Little Chesterford (GB); and Gemma Nicole Jones, Little Chesterford (GB)
Assigned to FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCÒLOGICA DE VALL HEBRON, Barcelona (ES); ASTRAZENECA UK LIMITED, Cambridge (GB); and XENTECH SAS, Evry (FR)
Appl. No. 16/956,112
Filed by Fundació Privada Institut D'Investigació Oncològica De Vall Hebron, Barcelona (ES); Astrazeneca UK Limited, Cambridge (GB); and Xentech SAS, Evry (FR)
PCT Filed Dec. 21, 2018, PCT No. PCT/EP2018/086759 § 371(c)(1), (2) Date Jun. 19, 2020, PCT Pub. No. WO2019/122411, PCT Pub. Date Jun. 27, 2019.
Claims priority of application No. 17382884 (EP), filed on Dec. 21, 2017.
Prior Publication US 2020/0319182 A1, Oct. 8, 2020
Int. Cl. G01N 33/574 (2006.01); A61K 31/166 (2006.01); A61K 31/407 (2006.01); A61K 31/4184 (2006.01); A61K 31/454 (2006.01); A61K 31/5025 (2006.01); A61K 31/55 (2006.01); A61K 31/551 (2006.01); A61P 35/00 (2006.01); G01N 33/50 (2006.01)

CPC G01N 33/574 (2013.01) [A61K 31/166 (2013.01); A61K 31/407 (2013.01); A61K 31/4184 (2013.01); A61K 31/454 (2013.01); A61K 31/5025 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); A61P 35/00 (2018.01); G01N 33/5091 (2013.01); G01N 33/5748 (2013.01); G01N 2333/916 (2013.01); G01N 2800/52 (2013.01)]

7 Claims

1. A method for the treatment of a cancer in a subject in need thereof, the method comprising the administration to said subject of a therapeutically effective amount of a PARP inhibitor agent, wherein the subject has been identified as responder to said PARP inhibitor agent by a method for predicting the response of a subject diagnosed with cancer to the PARP inhibitor agent which comprises:

i) determining the level of cells with RAD51 foci in a sample containing tumor cells isolated from said subject wherein the subject has not received, within 24 hours prior to the isolation of the sample, a chemotherapy selected from the group consisting of AC, FEC, ECF and navelbine/epirubicin, and

wherein the sample has not been treated with a method that induces DNA damage before determining the level of cells with RAD51 foci, and

ii) comparing the level obtained in step i) with a reference value, wherein:

a level of cells with RAD51 foci lower than said reference value indicates that the subject is predicted to respond to the PARP inhibitor agent, or

a level of cells with RAD51 foci equal or higher than said reference value, indicates that the subject is predicted not to respond to the PARP inhibitor agent.